Description:

Size: 100ul

Catalog no.: bs-3731R-A594

Price: 350 EUR

Product details

Gene ID Number

4846

Modification Site

Thr495

Swiss Prot

P29474

Tested applications

IF(IHC-P)

French translation

anticorps

Clonality

Polyclonal

Excitation emission

590nm/617nm

Target Antigen

eNOS Thr495

Concentration

1ug per 1ul

Immunogen range

470-520/1203

Modification

Phosphorylation

Crossreactivity

Human, Mouse, Rat

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Clone

Polyclonal antibody

Recommended dilutions

IF(IHC-P)(1:50-200)

Purification

Purified by Protein A.

Subcellular location

Cytoplasm, Cell membrane

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-eNOS Thr495 PAb ALEXA FLUOR 594

Specificity

This is a highly specific antibody against eNOS Thr495.

Long name

eNOS (Thr495) Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

KLH conjugated synthetic phosphopeptide derived from human eNOS around the phosphorylation site of Thr495

Synonyms

eNOS; ECNOS; Nitric oxide synthase, endothelial; Constitutive NOS; cNOS; EC-NOS; Endothelial NOS; NOS type III; NOSIII; NOS3

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.